Medical breakthrough: individualized gene therapy saves a child's life for the first time and opens new perspectives.


The world's first individualized therapy using gene editing
American doctors have made a medical breakthrough by creating and applying the world's first individualized therapy using gene editing to treat a 9.5-month-old boy with a rare genetic disorder.
According to The New York Times, the child named K.J. Muldun was born with a CPS1 deficiency - a rare genetic disorder. Doctors at the Children's Hospital of Philadelphia and the University of Pennsylvania developed a personalized treatment for K.J. based on CRISPR technology.
'In my opinion, this is one of the most potentially transformative technologies available,' said Dr. Peter Marks, former head of the gene therapy regulatory division of the U.S. Food and Drug Administration (FDA).
K.J. received three infusions of the experimental treatment. After the first dose, the child's condition significantly improved, and after the second, doctors were able to halve the dosage of medications that remove ammonia from his blood. The development and testing of gene editing for the baby took place in record Time.
Potential of CRISPR technology
The development of treatment for K.J. opens many possibilities for treating rare genetic disorders. Researchers believe that this technology could be successfully adapted to treat many other genetic diseases. The success of the project was made possible by decades of fundamental research and technological development.
Read also
- The government allocated 2.8 billion UAH for public roads
- The State Geological Survey prepared 60 plots for auctions for the sale of licenses for subsoil use
- Funeral Assistance 2025: new amounts and rules for pensioners and military personnel
- Fuel Prices in Kyiv Region: Gas Stations Showed How Much Gasoline, Diesel, and Autogas Cost
- Ukraine prepares an agritrade strategy with the European Union
- Zelensky approved the composition of the Ukrainian delegation for negotiations in Istanbul: who is on the list